Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MorphoSys acquires Sloning BioTechnology

This article was originally published in Scrip

Executive Summary

MorphoSys, the antibody technology company, is using some of its cash pile (approximately €150 milion as of June 2010) to improve the R&D productivity of its platform. MorphoSys is acquiring another Munich-based firm, Sloning BioTechnology, for €19 million cash to access its Slonomics technology which it says offers precise and rapid synthesis of protein libraries which should enable it to cut the time needed to generate an antibody drug candidate by a third.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts